A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Status:
Terminated
Trial end date:
2021-01-26
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum
tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with
acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic
leukemia (CMML).
The secondary objective is to evaluate evidence of clinical efficacy associated with
BAY2402234 in patients with AML (defined as Complete remission, Complete remission with
partial hematologic recovery), and MDS (defined as hematological improvement).